Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

UCB SA

UCB
Current price
184.4 EUR +1.36 EUR (+0.74%)
Last closed 181.5 EUR
ISIN BE0003739530
Sector Healthcare
Industry Biotechnology
Exchange Euronext Brussels
Capitalization 34 450 241 667 EUR
Yield for 12 month +177.54 %
1Y
3Y
5Y
10Y
15Y
UCB
21.11.2021 - 28.11.2021

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium. Address: Allée de la Recherche, 60, Brussels, Belgium, 1070

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

161.59 EUR

P/E ratio

148.7705

Dividend Yield

0.51 %

Current Year

+5 254 449 913 EUR

Last Year

+5 519 573 529 EUR

Current Quarter

+2 792 301 925 EUR

Last Quarter

+2 664 242 216 EUR

Current Year

+3 343 558 951 EUR

Last Year

+3 655 704 490 EUR

Current Quarter

+1 940 904 957 EUR

Last Quarter

+1 654 771 546 EUR

Key Figures UCB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 185 552 706 EUR
Operating Margin TTM 11.68 %
PE Ratio 148.7705
Return On Assets TTM 1.98 %
PEG Ratio 1.1623
Return On Equity TTM 2.67 %
Wall Street Target Price 161.59 EUR
Revenue TTM 5 456 544 269 EUR
Book Value 47.21 EUR
Revenue Per Share TTM
Dividend Share 1.36 EUR
Quarterly Revenue Growth YOY 10.8 %
Dividend Yield 0.51 %
Gross Profit TTM 3 774 760 000 EUR
Earnings per share 1.22 EUR
Diluted Eps TTM 1.22 EUR
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -33.8 %
Profit Margin 4.4 %

Dividend Analytics UCB

Champion - 10+ consecutive years of dividend increases

Dividend growth over 5 years

13 %

Continuous growth

14 years

Payout Ratio 5 years average

25 %

Dividend History UCB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate 1.36
Ex Dividend Date 26.04.2024
Forward Annual Dividend Yield 0.75 %
Last Split Factor 100:1
Payout Ratio
Last Split Date 04.01.1999
Dividend Date

Stock Valuation UCB

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 148.7705
Forward PE 25.4453
Enterprise Value Revenue 6.6729
Price Sales TTM 6.3397
Enterprise Value EBITDA 32.4369
Price Book MRQ 3.8027

Financials UCB

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators UCB

For 52 weeks

64.99 EUR 186.59 EUR
50 Day MA 168.39 EUR
Shares Short Prior Month
200 Day MA 136.34 EUR
Short Ratio
Shares Short
Short Percent